Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …

Epigenetic alterations, along with genetic alterations, have long been regarded as the most
important mechanism participating in carcinogenesis. DNA methylation, histone …

Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy
and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest …

The phosphatidylinositol 3-kinase signal transduction pathway members are often activated
in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral …

Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple
epigenetic modifications affecting signaling networks and act synergistically with …

The signalling system known as mammalian target of rapamycin (mTOR) is believed to be
required for several biological activities involving cell proliferation. The serine-threonine …

Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of
rapamycin (mTORC1). The phosphatidylinositol 3‐kinase/mTOR signal transduction …

Double/triple-hit lymphomas (DHL/THL) account for 5–10% of diffuse large B cell lymphoma
(DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC …

BET proteins, which influence gene expression and contribute to the development of cancer,
are epigenetic interpreters. Thus, BET inhibitors represent a novel form of epigenetic …

Purpose Despite high initial remission rates, most lymphomas relapse and require further
therapy. The mammalian target of rapamycin (mTOR) pathway is a validated target in mantle …